To our knowledge, this association has not been previously documented in the literature and thus warrants further investigation to evaluate its use in IDH1-mutant tumors, particularly gliomas, which were predicted to have the greatest sensitivity to this agent with or without IDH1 mutation. Here, IDH1 is linked to central nervous system cancer.